Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.75 is 69% above its 5-year average of -2.46, near the high end of its 5-year range (-3.21–-0.75).
67.95% above its 12-month average of -2.34.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.15.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.75
EARNINGS PER SHARE (EPS) AVG TTM
-2.34
EARNINGS PER SHARE (EPS) AVG 3Y
-2.48
EARNINGS PER SHARE (EPS) AVG 5Y
-2.46
EARNINGS PER SHARE (EPS) AVG 10Y
-2.51
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+67.95%
CURRENT VS 3Y AVG
+69.73%
CURRENT VS 5Y AVG
+69.47%
CURRENT VS 10Y AVG
+70.09%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Editas Medicine, Inc.
Market Cap
$438.47M
Earnings Per Share (EPS)
-0.75
TTM Avg
-2.34
3Y Avg
-2.48
5Y Avg
-2.46
Market Cap
$435.92M
Earnings Per Share (EPS)
-1.98
TTM Avg
-3.65
3Y Avg
-4.15
5Y Avg
-2.79
Market Cap
$440.53M
Earnings Per Share (EPS)
-2.45
TTM Avg
-1.70
3Y Avg
-1.35
5Y Avg
-1.20
Market Cap
$441.78M
Earnings Per Share (EPS)
0.55
TTM Avg
-3.62
3Y Avg
-10.86
5Y Avg
-15.74
Market Cap
$444.42M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.80
3Y Avg
-1.19
5Y Avg
-1.52
Market Cap
$450.74M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.30
3Y Avg
-0.53
5Y Avg
-0.29
Market Cap
$422.75M
Earnings Per Share (EPS)
-0.84
TTM Avg
-3.40
3Y Avg
-3.01
5Y Avg
-2.22
Market Cap
$452.78M
Earnings Per Share (EPS)
-0.72
TTM Avg
-0.65
3Y Avg
-0.60
5Y Avg
-0.64
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $438.47M | -0.75 | -2.34 | -2.48 | -2.46 |
| NeoGenomics, Inc. (NEO)vs › | $435.92M | -1.98 | -3.65 | -4.15 | -2.79 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.53M | -2.45 | -1.70 | -1.35 | -1.20 |
| Assembly Biosciences, Inc. (ASMB)vs › | $441.78M | 0.55 | -3.62 | -10.86 | -15.74 |
| NeuroPace, Inc. (NPCE)vs › | $444.42M | -0.57 | -0.80 | -1.19 | -1.52 |
| Ovid Therapeutics Inc. (OVID)vs › | $450.74M | -0.48 | -0.30 | -0.53 | -0.29 |
| Prothena Corporation plc (PRTA)vs › | $422.75M | -0.84 | -3.40 | -3.01 | -2.22 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $452.78M | -0.72 | -0.65 | -0.60 | -0.64 |
| NRC Health (NRC)vs › | $456.14M | 0.25 | 0.79 | 1.03 | 1.18 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.59M | -4.63 | -6.16 | -6.16 | -6.16 |
Trailing EPS (TTM)
$-0.75
Forward EPS (Est.)
$-0.78
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.80 |
| 2024-12-31 | -2.88 |
| 2023-12-31 | -2.02 |
| 2022-12-31 | -3.21 |
| 2021-12-31 | -2.85 |
| 2020-12-31 | -1.98 |
| 2019-12-31 | -2.47 |
| 2018-12-31 | -2.33 |
| 2017-12-31 | -2.98 |
| 2016-12-31 | -3.02 |
| 2015-12-31 | -2.04 |
| 2014-12-31 | -5.34 |
| 2013-12-31 | -0.18 |
